Hidradenitis Suppurativa: Two Successful Clinical Cases with Adalimumab
SPMI CASE REPORTS · 01.05.2024
DOI: 10.60591/crspmi.257 ↗Kurz gefasst
Fachartikel in der Zeitschrift SPMI CASE REPORTS, erschienen am 01.05.2024. Verfasst von Mariana Bessa Quelhas und 6 weiteren Autor:innen.
Abstract (Originalsprache)
Hidradenitis suppurativa is a chronic inflammatory disease that evolves in flares, characterized by painful nodules, abscesses, and fistulas, with a severe impact on patients' quality of life. Adalimumab is the first-line biological therapy in the treatment of severe hidradenitis suppurativa, preventing fistulasand scarring. This article presents two cases of severe hidradenitis suppurativa. The first is a 29-year-old woman with no significant personal background, and the second is a 70-year-old man with multiple diseases. Both patients were diagnosed with severe hidradenitis suppurativa requiring hospitalization to control the disease, and showed significant clinical improvement with adalimumab. This article aims to emphasize the importance of diagnostic suspicion in patients of all genders and ages and highlights the importance of an early therapy start, impacting the disease’s prognostic and the patient's quality of life.
Schlagwörter
Zitieren
APA
Quelhas, M. B., Silva, D. D. N., Dominguez, J., Moraes, M. D., Francine, Ríos, D. Á. D. L., & Manuel, J. (2024). Hidradenitis Suppurativa: Two Successful Clinical Cases with Adalimumab. SPMI CASE REPORTS. https://doi.org/10.60591/crspmi.257
Vancouver
Quelhas MB, Silva DDN, Dominguez J, Moraes MD, Francine, Ríos DÁDL, et al. Hidradenitis Suppurativa: Two Successful Clinical Cases with Adalimumab. SPMI CASE REPORTS. 2024. doi:10.60591/crspmi.257
BibTeX
@article{Quelhas2024,
author = {Quelhas, Mariana Bessa and Silva, Daniela do Nascimento and Dominguez, Joaquina and Moraes, Mascarenhas De and Francine and Ríos, Del Águila De Los and Manuel, José},
title = {Hidradenitis Suppurativa: Two Successful Clinical Cases with Adalimumab},
journal = {SPMI CASE REPORTS},
year = {2024},
doi = {10.60591/crspmi.257}
}
EUVIMED